engleski

Azithromycin in the Treatment of Chronic prostatitis Caused by Chlamydia trachomatis

C.trachomatis is the most common bacterial pathogen of sexually transmitted diseases. It causes up to 30% of chronic prostatitis cases. The aim of this study was to determine the efficacy of azithromycin in the treatment of chlamydial prostatitis. In the period from March 1, 1999 till August 31, 2001, at the Outpatient Department for Urogenital Infections of the University Hospital for Infectious Diseases "Dr Fran Mihaljević", Zagreb, Croatia, we examined a total of 75 patients with chlamydial prostatitis. The inclusion criteria for C.trachomatis prostatitis were clinical symptoms of chronic prostatitis, the presence of 10 or more WBCs/hpf in EPS or VB3, the presence of C.trachomatis in EPS or VB3, absence of C.trachomatis in urethral swab specimens and other possible pathogens of chronic prostatitis in VB1, VB2, EPS or VB3. The presence of C.trachomatis was examined by isolation, McCoy culture and Lugol stain. Azithromycin was administered in 75 patients with chlamydial prostatitis infection. All patients suffered from urethral, prostatic and/or sexual disorders. Azithromycin was administered 7-14 days after samples for microbiological analysis had been collected. Patients were treated with a total of 4.5 g of azithromycin for 3 weeks, given as a three-day therapy of 1x500 mg in regular time intervals of 4 days. Patients' sexual partners were treated at the same time. Clinical and bacteriological examination of patients was performed 4-6 weeks after the end of therapy. The effectiveness of conducted treatment was as follows: eradication in 61 patients (81.3%), symptoms disappearance in 60 patients (80%). In conclusion, our study demonstrated an excellent efficacy of azithromycin in the treatment of prostatitis chlamydial infections.

nije evidentirano

nije evidentirano